Oncodesign Precision Medicine (ZR8)

Overview

Oncodesign Precision Medicine (OPM) is a leading biopharmaceutical company that focuses on the precision medicine sector, particularly in addressing the critical challenges of resistant and metastatic cancers. Based in Dijon, France, OPM has dedicated its efforts towards developing innovative diagnostic and therapeutic solutions aimed at improving the outcomes for patients facing these aggressive forms of cancer. The company's significant progress and specialized expertise in precision medicine have positioned it as a pivotal player in the field of oncology. As of October 19, 2022, Oncodesign Precision Medicine Société anonyme has become a subsidiary of Edmond de Rothschild Equity Strategies Management III S.à.r.l., indicating a strategic collaboration poised to enhance its capabilities and reach in the global healthcare market.

Products and Services

Oncodesign Precision Medicine offers a range of diagnostic and therapeutic solutions aimed at tackling the complexities of resistant and metastatic cancers. These offerings are built on the company's robust research and development in precision medicine, delivering targeted, innovative solutions to the healthcare community.

• Diagnostic Solutions

  Oncodesign's diagnostic services focus on identifying biomarkers and specific cancer signatures that can guide the development of personalized treatment plans. Utilizing advanced molecular diagnostics and imaging techniques, these solutions are designed to accurately assess the progression and characteristics of the disease, enabling more precise and effective treatment strategies.

• Therapeutic Solutions

  The company's therapeutic solutions are centered around the development of targeted therapies and drugs that specifically address the unique genetic and molecular profiles of resistant and metastatic cancers. Through the integration of cutting-edge biotechnology and pharmacology, OPM aims to develop treatments that not only halt the progress of the disease but also reduce the potential for adverse side effects, thereby improving the quality of life for patients.